Default company panoramic image
Logo

Novadiscovery

Novadiscovery is an in silico IP factory geared towards superior R&D economics in high unmet need areas.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Lyon, RA, France
  • Currency EUR
  • Founded April 2010
  • Employees 12
  • Website novadiscovery.com

Company Summary

Novadiscovery ambitions to become the global leader in predictive modeling solutions applied to drug R&D. Our technology drives the development of efficient and targeted therapies for high unmet need patients in selected therapeutic areas (cancer, cardiovascular, infectious diseases & immunology). The company is structured as an IP factory which gets monetized through an asset-centric funding model and licensing agreements with big pharmas.

Team

  • Default avatar
    François-Henri Boissel
    Chief Executive Officer
    Unconfirmed

    MBA graduate from ESSEC Business School, François-Henri has spent 4 years with the investment bank Lehman Brothers in London and Tokyo specializing in asset-backed financing.
    He has developed an expertise in financial engineering, deal structuring and execution, as well as credit and market risk analysis.

  • Default avatar
    Jean-Pierre Boissel
    Chief Scientific Officer
    Unconfirmed

    Professor of clinical pharmacology at Claude Bernard Lyon 1 University since 1984 and author of more than 300 publications in peer-reviewed journals, Jean-Pierre is one of the founding fathers of systems biology.
    At the forefront of innovation in biomedical sciences throughout his career, he co-founded in 1988 the first CRO globally to set up a computer-based on-site system to collect and control clinic trials data.

Previous Investors

  • Default avatar
    Founders, family & friends
    Unconfirmed